Author response: Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals

Schwab N., Schneider-Hohendorf T., Pignolet B., Brassat D., Wiendl H.

Letter to the editor (journal) | Peer reviewed

Details about the publication

JournalNeurology
Volume95
Issue11
Page range505null
StatusPublished
Release year2020
Language in which the publication is writtenEnglish
DOI10.1212/WNL.0000000000010513
Link to the full texthttps://api.elsevier.com/content/abstract/scopus_id/85091051174
KeywordsPML

Authors from the University of Münster

Schneider-Hohendorf, Tilman
Department for Neurology